NCT02801097View on ClinicalTrials.gov

RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)

PHASE1TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 30, 2016

Primary Completion Date

November 22, 2018

Study Completion Date

December 9, 2019

Conditions
Malignant Solid TumorMetastatic CancerAdvanced Cancer
Interventions
DRUG

RRx-001

DRUG

Irinotecan

Trial Locations (2)

95817

University of California, Davis, Sacramento

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors

Lead Sponsor

EpicentRx, Inc.
All Listed Sponsors
lead

EpicentRx, Inc.

INDUSTRY